These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 34288423)

  • 1. Evaluation of pretreatment telomere length as a prognostic marker in intermediate-risk acute myeloid leukemia.
    Gu R; Cao J; Wei S; Gong X; Wang Y; Mi Y; Zhang J; Qiu S; Rao Q; Wang M; Wei H; Wang J
    Int J Lab Hematol; 2021 Dec; 43(6):1510-1515. PubMed ID: 34288423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature.
    Díaz-Beyá M; Brunet S; Nomdedéu J; Pratcorona M; Cordeiro A; Gallardo D; Escoda L; Tormo M; Heras I; Ribera JM; Duarte R; de Llano MP; Bargay J; Sampol A; Nomdedeu M; Risueño RM; Hoyos M; Sierra J; Monzo M; Navarro A; Esteve J;
    Oncotarget; 2015 Oct; 6(31):31613-27. PubMed ID: 26436590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative Telomere Length before Hematopoietic Cell Transplantation and Outcome after Unrelated Donor Hematopoietic Cell Transplantation for Acute Leukemia.
    Wang Y; Wang T; Dagnall C; Haagenson M; Spellman SR; Hicks B; Jones K; Lee SJ; Savage SA; Gadalla SM
    Biol Blood Marrow Transplant; 2017 Jul; 23(7):1054-1058. PubMed ID: 28389255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia.
    Chretien AS; Fauriat C; Orlanducci F; Rey J; Borg GB; Gautherot E; Granjeaud S; Demerle C; Hamel JF; Cerwenka A; von Strandmann EP; Ifrah N; Lacombe C; Cornillet-Lefebvre P; Delaunay J; Toubert A; Arnoulet C; Vey N; Olive D
    Oncotarget; 2017 Jul; 8(30):49548-49563. PubMed ID: 28548938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia.
    Ribeiro AF; Pratcorona M; Erpelinck-Verschueren C; Rockova V; Sanders M; Abbas S; Figueroa ME; Zeilemaker A; Melnick A; Löwenberg B; Valk PJ; Delwel R
    Blood; 2012 Jun; 119(24):5824-31. PubMed ID: 22490330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: An analysis from the acute leukemia working party of the EBMT.
    Canaani J; Labopin M; Socié G; Nihtinen A; Huynh A; Cornelissen J; Deconinck E; Gedde-Dahl T; Forcade E; Chevallier P; Bourhis JH; Blaise D; Mohty M; Nagler A
    Am J Hematol; 2017 Jul; 92(7):653-659. PubMed ID: 28370339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities.
    Gröschel S; Lugthart S; Schlenk RF; Valk PJ; Eiwen K; Goudswaard C; van Putten WJ; Kayser S; Verdonck LF; Lübbert M; Ossenkoppele GJ; Germing U; Schmidt-Wolf I; Schlegelberger B; Krauter J; Ganser A; Döhner H; Löwenberg B; Döhner K; Delwel R
    J Clin Oncol; 2010 Apr; 28(12):2101-7. PubMed ID: 20308656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telomere length is an independent prognostic marker in MDS but not in de novo AML.
    Williams J; Heppel NH; Britt-Compton B; Grimstead JW; Jones RE; Tauro S; Bowen DT; Knapper S; Groves M; Hills RK; Pepper C; Baird DM; Fegan C
    Br J Haematol; 2017 Jul; 178(2):240-249. PubMed ID: 28486748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Copy-number analysis identified new prognostic marker in acute myeloid leukemia.
    Nibourel O; Guihard S; Roumier C; Pottier N; Terre C; Paquet A; Peyrouze P; Geffroy S; Quentin S; Alberdi A; Abdelali RB; Renneville A; Demay C; Celli-Lebras K; Barbry P; Quesnel B; Castaigne S; Dombret H; Soulier J; Preudhomme C; Cheok MH
    Leukemia; 2017 Mar; 31(3):555-564. PubMed ID: 27686867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monosomal karyotype as an adverse prognostic factor in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem-cell transplantation in first complete remission: a retrospective survey on behalf of the ALWP of the EBMT.
    Brands-Nijenhuis AV; Labopin M; Schouten HC; Volin L; Socié G; Cornelissen JJ; Huynh A; Ljungman P; Malard F; Esteve J; Nagler A; Mohty M
    Haematologica; 2016 Feb; 101(2):248-55. PubMed ID: 26589909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia.
    Díaz-Beyá M; Brunet S; Nomdedéu J; Cordeiro A; Tormo M; Escoda L; Ribera JM; Arnan M; Heras I; Gallardo D; Bargay J; Queipo de Llano MP; Salamero O; Martí JM; Sampol A; Pedro C; Hoyos M; Pratcorona M; Castellano JJ; Nomdedeu M; Risueño RM; Sierra J; Monzó M; Navarro A; Esteve J
    Blood Cancer J; 2015 Oct; 5(10):e352. PubMed ID: 26430723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genome-wide identification of FHL1 as a powerful prognostic candidate and potential therapeutic target in acute myeloid leukaemia.
    Fu Y; Xu M; Cui Z; Yang Z; Zhang Z; Yin X; Huang X; Zhou M; Wang X; Chen C
    EBioMedicine; 2020 Feb; 52():102664. PubMed ID: 32062360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence for a pre-existing telomere deficit in non-clonal hematopoietic stem cells in patients with acute myeloid leukemia.
    Ventura Ferreira MS; Crysandt M; Ziegler P; Hummel S; Wilop S; Kirschner M; Schemionek M; Jost E; Wagner W; Brümmendorf TH; Beier F
    Ann Hematol; 2017 Sep; 96(9):1457-1461. PubMed ID: 28674830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic importance of histone methyltransferase MLL5 expression in acute myeloid leukemia.
    Damm F; Oberacker T; Thol F; Surdziel E; Wagner K; Chaturvedi A; Morgan M; Bomm K; Göhring G; Lübbert M; Kanz L; Fiedler W; Schlegelberger B; Heil G; Schlenk RF; Döhner K; Döhner H; Krauter J; Ganser A; Heuser M
    J Clin Oncol; 2011 Feb; 29(6):682-9. PubMed ID: 21205756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between DNMT3A mutations and prognosis of adults with de novo acute myeloid leukemia: a systematic review and meta-analysis.
    Tie R; Zhang T; Fu H; Wang L; Wang Y; He Y; Wang B; Zhu N; Fu S; Lai X; Shi J; Huang H
    PLoS One; 2014; 9(6):e93353. PubMed ID: 24936645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia.
    Oran B; Jorgensen JL; Marin D; Wang S; Ahmed S; Alousi AM; Andersson BS; Bashir Q; Bassett R; Lyons G; Chen J; Rezvani K; Popat U; Kebriaei P; Patel K; Rondon G; Shpall EJ; Champlin RE
    Haematologica; 2017 Jan; 102(1):110-117. PubMed ID: 27540139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic architecture and treatment outcome in pediatric acute myeloid leukemia: a Children's Oncology Group report.
    Vujkovic M; Attiyeh EF; Ries RE; Goodman EK; Ding Y; Kavcic M; Alonzo TA; Wang YC; Gerbing RB; Sung L; Hirsch B; Raimondi S; Gamis AS; Meshinchi S; Aplenc R
    Blood; 2017 Jun; 129(23):3051-3058. PubMed ID: 28411282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 4-gene expression prognostic signature might guide post-remission therapy in patients with intermediate-risk cytogenetic acute myeloid leukemia.
    Torrebadell M; Díaz-Beyá M; Kalko SG; Pratcorona M; Nomdedeu J; Navarro A; Gel B; Brunet S; Sierra J; Camós M; Esteve J
    Leuk Lymphoma; 2018 Oct; 59(10):2394-2404. PubMed ID: 29390924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive significance of the European LeukemiaNet classification of genetic aberrations in patients with acute myeloid leukaemia undergoing allogeneic stem cell transplantation.
    Hemmati PG; Vuong LG; Terwey TH; Jehn CF; le Coutre P; Penack O; Na IK; Dörken B; Arnold R
    Eur J Haematol; 2017 Feb; 98(2):160-168. PubMed ID: 27706846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.